March 10, 2021
Japan’s first off-year drug re-pricing next month will hit some 70% of major products at 41 companies, including Chugai Pharmaceutical’s Avastin (bevacizumab), Takeda Pharmaceutical’s Takecab (vonoprazan), and Daiichi Sankyo’s Nexium (esomeprazole), a Jiho survey showed. The survey drew responses from...read more